TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8612442

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: Maternal history of diabetes
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: Paternal history of diabetes
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: Alcohol use > 30 g/day
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: Dietary intake (total protein, animal protein, polyunsaturated fatty acids)
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: Alcohol use ≤ 30 g/day
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 2484

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 2484
Study: 2184513

Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Ketoconazole (400 mg daily)
Number of subjects: 37
Study: 7033353

Group type: EXPERIMENTAL
Intervention: Sucralfate (4 grams in four divided doses each day)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg three times a day, 400 mg at night)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Cimetidine (control group)
Number of subjects: 112
Study: 31498141

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive rehabilitation (CACR) using the ERICA platform
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard cognitive training (SCT)
Number of subjects: 60
Study: 28337719

Group type: EXPERIMENTAL
Intervention: Adherence intervention to nebulised and inhaled antibiotics
Number of subjects: 2979
Study: 25889280

Group type: EXPERIMENTAL
Intervention: Food neophobia (measured using the Child Food Neophobia Scale)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (NOURISH RCT)
Number of subjects: 330
Study: 23712193

Group type: EXPERIMENTAL
Intervention: Resin bonded bridgework (test group, n=40 patients)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (n=42 patients)
Number of subjects: 82
Study: 21849024

Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR) program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 200
Study: 19215005

Group type: EXPERIMENTAL
Intervention: Auscultation by cardiology attendings
Number of subjects: 100

Group type: COMPARATOR
Intervention: Auscultation by cardiology fellows, residents, and interns
Number of subjects: 100

Group type: COMPARATOR
Intervention: Acoustic cardiography
Number of subjects: 100
Study: 15847961

Group type: EXPERIMENTAL
Intervention: Mexican ethnic group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Puerto Rican ethnic group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cuban and Dominican ethnic groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social determinants of health
Number of subjects: 0
Study: 12211217

Group type: EXPERIMENTAL
Intervention: Orlistat with selected concomitant medications (amitriptyline, atorvastatin, cyclosporine, losartan, metformin, phentermine, and sibutramine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective concomitant medications and orlistat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective concomitant medications alone
Number of subjects: 0
Study: 10573044

Group type: EXPERIMENTAL
Intervention: Leflunomide treatment (20 mg/d)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Methotrexate treatment (7.5-15 mg/wk)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 482
Study: 8918487

Group type: EXPERIMENTAL
Intervention: Chemotherapy (carboplatin, etoposide, and bleomycin)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy (carboplatin, etoposide, bleomycin, and cyclophosphamide)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Chemotherapy only (without irradiation)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Germinomas
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Nongerminomatous GCT (NGGCT)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Survival without relapse or progression
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Tumor recurrence or progression
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Successful salvage therapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Survival probability
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Toxicity associated with study chemotherapy
Number of subjects: 71
Study: 2021382

Group type: EXPERIMENTAL
Intervention: Unannounced sudden increase of the pain stimulus during the working-up procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Predictable pattern of pain stimuli
Number of subjects: 0
Study: 6284334

Group type: EXPERIMENTAL
Intervention: Delta-9-THC
Number of subjects: 214

Group type: COMPARATOR
Intervention: Prochlorperazine (Compazine)
Number of subjects: 214
Study: 30929283

Group type: EXPERIMENTAL
Intervention: Compassion meditation (CM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Veteran.calm (VC)
Number of subjects: 28
Study: 28323444

Group type: EXPERIMENTAL
Intervention: Countermeasures (6 types varying by type and modality)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Multistage alerts
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Auditory‐visual coffee cup icon
Number of subjects: 72

Group type: COMPARATOR
Intervention: No countermeasure (baseline comparison)
Number of subjects: 72
Study: 25908486

Group type: EXPERIMENTAL
Intervention: Dexamethasone implant
Number of subjects: 40
Study: 24174657

Group type: EXPERIMENTAL
Intervention: Thyroid hormone (TH) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without IVH)
Number of subjects: 0
Study: 20602123

Group type: EXPERIMENTAL
Intervention: Customised orthotic insoles (treatment group, n = 73)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Nothing (control group, n = 147)
Number of subjects: 228
Study: 18853141

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 113
Study: 17372175

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of isosorbide dinitrate and hydralazine hydrochloride (FDC I/H)
Number of subjects: 1050
Study: 16099137

Group type: EXPERIMENTAL
Intervention: Word Completion Memory Test (WCMT)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Neuropsychological functioning tests and simulation tests
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: WCMT and two additional simulation measures
Number of subjects: 71
Study: 12373658

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study: 10349954

Group type: EXPERIMENTAL
Intervention: Changing heat and moisture exchangers every 48 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Changing heat and moisture exchangers every 24 hours
Number of subjects: 0
Study: 7853170

Group type: EXPERIMENTAL
Intervention: Abecarnil (10, 20, 40 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alprazolam (1.0, 2.0, 4.0 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alprazolam (high dose)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Abecarnil (high dose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2014889

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with diamorphine 0.0025%
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with fentanyl 0.0002%
Number of subjects: 61

Group type: COMPARATOR
Intervention: bupivacaine 0.125%
Number of subjects: 61
Study: 7080851

Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol decanoate injections (20 times and thereafter 15 times the optimal oral haloperidol dose)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol decanoate injections
Number of subjects: 11
Study: 30052475

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 24
Study: 29845329

Group type: EXPERIMENTAL
Intervention: Trastuzumab (T), 5-FU (F)/capecitabine (X), and cisplatin (P)
Number of subjects: 155
Study: 26410538

Group type: EXPERIMENTAL
Intervention: 6-month behavioral lifestyle intervention
Number of subjects: 143

Group type: COMPARATOR
Intervention: Usual presurgical care
Number of subjects: 143
Study: 24701585

Group type: EXPERIMENTAL
Intervention: Intrathecal anesthesia with levobupivacaine (Group S)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with propofol (Group T)
Number of subjects: 60
Study: 22240407

Group type: EXPERIMENTAL
Intervention: Azithromycin (30 mg/kg oral dose)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Benzathine benzylpenicillin (50,000 units/kg intramuscular injection)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 250

Group type: COMPARATOR
Intervention: Benzathine benzylpenicillin
Number of subjects: 250
Study: 20404280

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 162

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 162
Study: 17959952

Group type: EXPERIMENTAL
Intervention: Esmolol (continuous infusion of 5-15 microg x kg(‐1) x min(‐1))
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (intermittent doses of fentanyl)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Remifentanil (continuous infusion of 0.1-0.5 microg x kg(‐1) x min(‐1))
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Esmolol (continuous infusion)
Number of subjects: 90
Study: 15886232

Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Number of subjects: 451

Group type: COMPARATOR
Intervention: Conventional insulin treatment
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Nonsurvivors
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Postmortem liver D1 activity
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Postmortem skeletal muscle D3 activity
Number of subjects: 451
Study: 14727969

Group type: EXPERIMENTAL
Intervention: Early invasive strategy combined with early use of tirofiban and standard medical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapeutic management options
Number of subjects: 0
Study: 9521971

Group type: EXPERIMENTAL
Intervention: Dorsal Penile Nerve Block (DPNB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: EMLA cream (0.5 g topically 1 hour before circumcision)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Circumcision without anesthesia (20 term newborns)
Number of subjects: 50

Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 50
Study: 7619356

Group type: EXPERIMENTAL
Intervention: 7.5 mg/day moexipril
Number of subjects: 108

Group type: COMPARATOR
Intervention: 180 mg/day verapamil-SR
Number of subjects: 108
Study: 2229460

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 897627

Group type: EXPERIMENTAL
Intervention: Extreme haemodilution with autologous transfusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Moderate haemodilution
Number of subjects: 60
Study: 31597530

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Bipolar electrocautery
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 31799616

Group type: EXPERIMENTAL
Intervention: Multielectrode tDCS of the left DLPFC
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Multielectrode tDCS of the right DLPFC
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 25
Study: 30170468

Group type: EXPERIMENTAL
Intervention: Midazolam premedication
Number of subjects: 128
Study: 27108826

Group type: EXPERIMENTAL
Intervention: Anaesthetic trainee doctors
Number of subjects: 85

Group type: COMPARATOR
Intervention: Nursing anaesthetic assistants
Number of subjects: 85
Study: 24711842

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 40
Study: 22858124

Group type: EXPERIMENTAL
Intervention: 10 mg/day lutein
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 20 mg/day lutein
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 10 mg/day lutein plus 10 mg/day zeaxanthin
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 21091279

Group type: EXPERIMENTAL
Intervention: FTC‐TDF (emtricitabine and tenofovir disoproxil fumarate)
Number of subjects: 2499

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2499
Study: 18717569

Group type: EXPERIMENTAL
Intervention: Juice blend (JB), MonaVie Active
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15650890

Group type: EXPERIMENTAL
Intervention: Midvastus approach
Number of subjects: 50
Study: 12705112

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Inactive women without HRT
Number of subjects: 239
Study: 10588987

Group type: EXPERIMENTAL
Intervention: HFA‐BDP (QVAR)
Number of subjects: 31

Group type: COMPARATOR
Intervention: CFC‐BDP (Beclovent)
Number of subjects: 31
Study: 8762730

Group type: EXPERIMENTAL
Intervention: dexfenfluramine (d-FF) 15 mg twice daily for 6 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 1915397

Group type: EXPERIMENTAL
Intervention: Cefoperazone plus aztreonam every 4 hours
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Cefoperazone plus aztreonam every 8 hours
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Cefoperazone plus aztreonam
Number of subjects: 478
Study: 7038148

Group type: EXPERIMENTAL
Intervention: Deliberate pre‐transplant blood transfusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random transfusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: No transfusions
Number of subjects: 0
Study: 31972610

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich high-fiber diet
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Protein-rich high-fiber diet
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Unsaturated fat-rich high-fiber diet
Number of subjects: 164
Study: 30323234

Group type: EXPERIMENTAL
Intervention: New administration route (NEW.AR) of alprostadil cream
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard administration route (ST.AR) of alprostadil cream
Number of subjects: 71
Study: 29467437

Group type: EXPERIMENTAL
Intervention: Accelerated rTMS (n = 58): 63,000 high frequency rTMS pulses delivered as 3 treatments per day over 3 days in week 1, 3 treatments over 2 days in week 2 and 3 treatments on a single day in week 3
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard rTMS (n = 57): 63,000 total high frequency rTMS pulses delivered over 5 days per week for 4 weeks
Number of subjects: 115
Study: 27414655

Group type: EXPERIMENTAL
Intervention: CYD‐TDV (recombinant live attenuated tetravalent dengue vaccine)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CYD‐TDV
Number of subjects: 18
Study: 24633488

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrM) + carbohydrate (CHO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo CHO
Number of subjects: 20
Study: 22846190

Group type: EXPERIMENTAL
Intervention: Vacuum interferential current (IFC) therapy, 12 sessions over 4 weeks.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo therapy, 12 sessions over 4 weeks.
Number of subjects: 58
Study: 20171127

Group type: EXPERIMENTAL
Intervention: Benzodiazepine hypnotics and Z-drugs (e.g., zolpidem, zopiclone, zaleplon)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Benzodiazepine hypnotics and Z-drugs
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Benzodiazepine hypnotics and Z-drugs with alcohol co-administration
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Repeated daily use of hypnotic drugs
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Zolpidem and zopiclone
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Zaleplon
Number of subjects: 57
Study: 19112511

Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccine (OPV) at birth
Number of subjects: 4345

Group type: COMPARATOR
Intervention: Not receiving OPV at birth (Control)
Number of subjects: 4345
Study: 15853109

Group type: EXPERIMENTAL
Intervention: Optibond dual cure (OPTB) with light-curing (LC) and combination of light and chemical curing (LCC)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Light-curing (LC) and combination of light and chemical curing (LCC)
Number of subjects: 72
Study: 12816339

Group type: EXPERIMENTAL
Intervention: context/specific questions
Number of subjects: 236

Group type: COMPARATOR
Intervention: noncontext/label questions
Number of subjects: 236

Group type: COMPARATOR
Intervention: noncontext/specific questions
Number of subjects: 236

Group type: COMPARATOR
Intervention: context/label questions
Number of subjects: 236
Study: 10676865

Group type: EXPERIMENTAL
Intervention: 5% CO2 added to the inspiratory gas mixture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Increased venous pressure to fill the pulmonary vascular bed
Number of subjects: 30
Study: 9060198

Group type: EXPERIMENTAL
Intervention: Relapse prevention programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Discussion control group
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-additional treatment control group
Number of subjects: 60
Study: 8457152

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (20-Gy) + postoperative low-dose external-beam radiotherapy (35- to 40-Gy)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Postoperative high-dose external-beam radiotherapy (50- to 55-Gy) alone (Control)
Number of subjects: 35
Study: 3636335

Group type: EXPERIMENTAL
Intervention: Timentin alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Timentin in combination with amikacin
Number of subjects: 100
Study: 29855611

Group type: EXPERIMENTAL
Intervention: RT Prepare intervention (two consultations with a radiation therapist)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 408
Study: 28821271

Group type: EXPERIMENTAL
Intervention: High-speed resistance training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-speed resistance training plus balance exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 26073872

Group type: EXPERIMENTAL
Intervention: Dexmecamylamine 2 mg
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Dexmecamylamine 1 mg
Number of subjects: 768

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 768
Study: 22903360

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention for body image disturbance
Number of subjects: 38

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 38
Study: 21696738

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High Hcy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low Hcy
Number of subjects: 33
Study: 18326731

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.4 mg/kg bolus followed by 0.4 mg/kg/h continuous infusion for 120 minutes)
Number of subjects: 12
Study: 16782912

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg by mouth twice daily)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 12932066

Group type: EXPERIMENTAL
Intervention: Unilateral spinal anaesthesia with hyperbaric bupivacaine 7.5 mg 0.5% (Group Spinal)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Volatile induction and maintenance anaesthesia with sevoflurane (Group SEVO)
Number of subjects: 30
Study: 11119192

Group type: EXPERIMENTAL
Intervention: Propofol (12 mg.kg(‐1).h(‐1)) and alfentanil (0.04 mg.kg(‐1).h(‐1))
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sevoflurane 1-1.2 MAC in 30% O(2)/70% N(2)O
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ketamine racemate (10-12 mg.kg(‐1).h(‐1)) and midazolam (0.3-0.6 mg.kg(‐1).h(‐1))
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Halothane 1-1.2 MAC in 30% O(2)/70% N(2)O
Number of subjects: 39
Study: 9194018

Group type: EXPERIMENTAL
Intervention: Experiential-existential group psychotherapy (EEGP) program for 13 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control (WLC) condition
Number of subjects: 0
Study: 8241695

Group type: EXPERIMENTAL
Intervention: Ubiquinone (coenzyme Q10), 100 mg/day for 7 months
Number of subjects: 0
Study: 31563743

Group type: EXPERIMENTAL
Intervention: Nutritional intervention based on the Transtheoretical Model and Paulo Freire's pedagogy, consisting of 12 educational activities over 7 months.
Number of subjects: 1483

Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 1483
Study: 29212528

Group type: EXPERIMENTAL
Intervention: Robot-assisted training using the Armeo®Spring robot for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional occupational and physical therapy
Number of subjects: 0
Study: 25575541

Group type: EXPERIMENTAL
Intervention: Rituximab plus recombinant human thrombopoietin (rhTPO)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 115
Study: 25637728

Group type: EXPERIMENTAL
Intervention: Accelerated protocol (ACCEL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Slow protocol (SLOW)
Number of subjects: 40
Study: 23513469

Group type: EXPERIMENTAL
Intervention: Fresh lime
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 100
Study: 19880138

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (not specified dosage or duration)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 191
Study: 17696962

Group type: EXPERIMENTAL
Intervention: High-dose esomeprazole (40 mg b.d.)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Low-dose esomeprazole (40 mg o.d.)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240